Methods for Administering Aripiprazole
First Claim
1. An injectable composition that is free of sustained release matrices for the extended release of aripiprazole comprising a suspension of about 50 mg or more aripiprazole in an injection vehicle optionally comprising a viscosity enhancing agent, wherein the concentration of aripiprazole in the injectable composition is about 30 mg/ml or more wherein upon injection of the composition into an individual, the aripiprazole is present in the plasma of the individual for about 7 days or more.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.
0 Citations
22 Claims
- 1. An injectable composition that is free of sustained release matrices for the extended release of aripiprazole comprising a suspension of about 50 mg or more aripiprazole in an injection vehicle optionally comprising a viscosity enhancing agent, wherein the concentration of aripiprazole in the injectable composition is about 30 mg/ml or more wherein upon injection of the composition into an individual, the aripiprazole is present in the plasma of the individual for about 7 days or more.
- 15. A composition comprising a suspension of about 50 mg or more of aripiprazole and an aqueous injection vehicle comprising water, a viscosity enhancing agent, a wetting agent, and a tonicity agent wherein the composition is free of sustained release materials and wherein the concentration of aripiprazole in the composition is about 30 mg/ml or more.
Specification